Dateline City:
WHITEHOUSE STATION, N.J.
Exploratory Analyses in Advanced Melanoma and NSCLC Presented in Oral Session
Dr. Roger Perlmutter to Present at AACR Opening Plenary Session
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the presentation of early findings from studies
exploring the relationship between tumor PD-L1 expression and clinical
outcomes following monotherapy treatment with MK-3475, an
investigational anti-PD-1 immunotherapy, in patients with advanced
melanoma and advanced non-small cell lung cancer (NSCLC).
Language:
English
Contact:
Media:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more